Brepocitinib Beneficial for Moderate-to-Severe Psoriatic Arthritis

THURSDAY, May 18, 2023 -- For patients with moderately to severely active psoriatic arthritis, the tyrosine kinase 2/Janus kinase 1 inhibitor brepocitinib is effective for reducing symptoms, according to a study published online May 17 in Arthritis...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news